Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2013

Open Access 01-12-2013 | Research

The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro

Authors: Riccardo Adamo, Alessandro Comandini, Angelo Aquino, Laura Bonmassar, Loredana Guglielmi, Enzo Bonmassar, Ornella Franzese

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2013

Login to get access

Abstract

Background

Saquinavir, a protease inhibitor utilized in HIV infection, shows antitumor activity in various experimental models. In previous studies performed in our laboratory the drug was found to induce a substantial increase of telomerase activity in normal peripheral blood mononuclear cells. Aim of the present investigation was to test whether saquinavir was able to increase telomerase activity and the expression of the catalytic subunit of telomerase, hTERT, in human malignant hematopoietic cells.

Methods

Human Jurkat CD4+ T cell leukaemia cell line was used throughout the present study. The antiproliferative effect of saquinavir was tested by the MTT assay. Telomerase activity was determined according to the telomeric repeat amplification protocol. The expression of hTERT mRNA was semi-quantitative evaluated by RT-PCR amplification and quantitative Real Time PCR. The binding of the transcription factor c-Myc to its specific E-Box DNA binding-site of hTERT promoter was analyzed by Electophoretic Mobility Shift Assay (EMSA). The amount of c-Myc in cytoplasm and nucleus of leukemia cells was determined by Western Blot analysis, and c-Myc down-regulation was obtained by siRNA transfection.

Results

Saquinavir produced a substantial increase of telomerase activity in Jurkat cells in vitro without increasing but rather reducing target cell proliferation rate. Telomerase up-regulation appeared to be the result of enhanced expression of hTERT. Saquinavir-mediated up-regulation of hTERT gene was the result of the increased binding of proteins to the E-Box sequence of the promoter. Moreover, saquinavir amplified the expression of c-Myc especially in the nuclear cell fraction. The direct influence of saquinavir on this transcription factor was also demonstrated by the antagonistic effect of the drug on siRNA induced c-Myc suppression. Since c-Myc is the main responsible for hTERT transcription, these findings suggest that the main mechanism underlying saquinavir-induced telomerase activation is mediated by c-Myc up-regulation.

Conclusions

Saquinavir augments hTERT expression while inhibiting leukemic cell growth. Experimental evidences show that this effect is mediated by saquinavir-influenced increase of c-Myc levels. This could have relevance in terms of enhanced hTERT-dependent tumor cell immunogenicity and suggests new paharmacological approaches interfering with c-Myc dependent pathways.
Appendix
Available only for authorised users
Literature
1.
go back to reference Andreoni M, Perno CF: Positioning of HIV-protease inhibitors in clinical practice. Eur Rev Med Pharmacol Sci. 2012, 16: 10-18. Andreoni M, Perno CF: Positioning of HIV-protease inhibitors in clinical practice. Eur Rev Med Pharmacol Sci. 2012, 16: 10-18.
2.
go back to reference D’Alessandro A, Pieroni L, Ronci M, D’Aguanno S, Federici G: Proteasome inhibitors therapeutic strategies for cancer. Recent Pat Anticancer Drug Discov. 2009, 4: 73-82. 10.2174/157489209787002452.CrossRef D’Alessandro A, Pieroni L, Ronci M, D’Aguanno S, Federici G: Proteasome inhibitors therapeutic strategies for cancer. Recent Pat Anticancer Drug Discov. 2009, 4: 73-82. 10.2174/157489209787002452.CrossRef
3.
go back to reference Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B: Antitumour effects of antiretroviral therapy. Nat Rev Cancer. 2004, 4: 861-875. 10.1038/nrc1479.CrossRef Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B: Antitumour effects of antiretroviral therapy. Nat Rev Cancer. 2004, 4: 861-875. 10.1038/nrc1479.CrossRef
4.
go back to reference Toschi E, Sgadari C, Malavasi L, Bacigalupo I, Chiozzini C: Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinase’s. Int J Cancer. 2011, 128: 82-93. 10.1002/ijc.25550.CrossRef Toschi E, Sgadari C, Malavasi L, Bacigalupo I, Chiozzini C: Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinase’s. Int J Cancer. 2011, 128: 82-93. 10.1002/ijc.25550.CrossRef
5.
go back to reference Donia M, Maksimovic-Ivanic D, Mijatovic S, Mojic M, Miljkovic D, Timotijevic G, et al: In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle. 2011, 10: 492-499. 10.4161/cc.10.3.14727.CrossRef Donia M, Maksimovic-Ivanic D, Mijatovic S, Mojic M, Miljkovic D, Timotijevic G, et al: In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle. 2011, 10: 492-499. 10.4161/cc.10.3.14727.CrossRef
6.
go back to reference Rothweiler F, Michaelis M, Brauer P, Otte J, Weber K, Fehse B, et al: Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia. 2010, 12: 1023-1030.CrossRef Rothweiler F, Michaelis M, Brauer P, Otte J, Weber K, Fehse B, et al: Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia. 2010, 12: 1023-1030.CrossRef
7.
go back to reference McLean K, VanDeVen NA, Sorenson DR, Daudi S, Liu J: The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells. Gynecol Oncol. 2009, 112: 23-630.CrossRef McLean K, VanDeVen NA, Sorenson DR, Daudi S, Liu J: The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells. Gynecol Oncol. 2009, 112: 23-630.CrossRef
8.
go back to reference Franzese O, Comandini FA, Lombardi A, Saponiero A, Bonmassar E: Saquinavir up-regulates telomerase activity in lymphocytes activated with monoclonal antibodies against CD3/CD28. J Chemother. 2001, 4: 384-388.CrossRef Franzese O, Comandini FA, Lombardi A, Saponiero A, Bonmassar E: Saquinavir up-regulates telomerase activity in lymphocytes activated with monoclonal antibodies against CD3/CD28. J Chemother. 2001, 4: 384-388.CrossRef
9.
go back to reference Franzese O, Lombardi A, Comandini A, Cannavò E, Testorelli C, Cirello I, et al: Effect of Saquinavir on proliferation and telomerase activity of human peripheral blood mononuclear cells. Life Sci. 2001, 9: 1509-1520.CrossRef Franzese O, Lombardi A, Comandini A, Cannavò E, Testorelli C, Cirello I, et al: Effect of Saquinavir on proliferation and telomerase activity of human peripheral blood mononuclear cells. Life Sci. 2001, 9: 1509-1520.CrossRef
10.
go back to reference Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al: HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002, 8: 225-232. 10.1038/nm0302-225.CrossRef Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al: HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002, 8: 225-232. 10.1038/nm0302-225.CrossRef
11.
go back to reference Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH: The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res. 2002, 62: 5230-5235. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH: The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res. 2002, 62: 5230-5235.
12.
go back to reference Timeus F, Crescenzio N, Ricotti E, Doria A, Bertin D: The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines. Haematologica. 2006, 91: 711-712. Timeus F, Crescenzio N, Ricotti E, Doria A, Bertin D: The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines. Haematologica. 2006, 91: 711-712.
13.
go back to reference Shay JW, Wright WE: Role of telomeres and telomerase in cancer. Semin Cancer Biol. 2011, 21: 349-353. 10.1016/j.semcancer.2011.10.001.CrossRef Shay JW, Wright WE: Role of telomeres and telomerase in cancer. Semin Cancer Biol. 2011, 21: 349-353. 10.1016/j.semcancer.2011.10.001.CrossRef
14.
go back to reference Vonderheide RH: Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 2002, 21: 674-679. 10.1038/sj.onc.1205074.CrossRef Vonderheide RH: Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 2002, 21: 674-679. 10.1038/sj.onc.1205074.CrossRef
15.
go back to reference Wenandy L, Sorensen RB, Sengelov L, Svane IM, Thor Straten P, Andersen MH: The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res. 2008, 14: 4-7. 10.1158/1078-0432.CCR-07-4590.CrossRef Wenandy L, Sorensen RB, Sengelov L, Svane IM, Thor Straten P, Andersen MH: The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res. 2008, 14: 4-7. 10.1158/1078-0432.CCR-07-4590.CrossRef
16.
go back to reference Tian X, Chen B, Liu X: Telomere and telomerase as targets for cancer therapy. Appl Biochem Biotechnol. 2010, 160: 1460-1472. 10.1007/s12010-009-8633-9.CrossRef Tian X, Chen B, Liu X: Telomere and telomerase as targets for cancer therapy. Appl Biochem Biotechnol. 2010, 160: 1460-1472. 10.1007/s12010-009-8633-9.CrossRef
17.
go back to reference Niu BL, Du HM, Shen HP, Lian ZR, Li JZ, Lai X, et al: Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine. Vaccine. 2012, 30: 3395-3404. 10.1016/j.vaccine.2012.03.045.CrossRef Niu BL, Du HM, Shen HP, Lian ZR, Li JZ, Lai X, et al: Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine. Vaccine. 2012, 30: 3395-3404. 10.1016/j.vaccine.2012.03.045.CrossRef
18.
go back to reference Pepponi R, Marra G, Fuggetta MP, Falcinelli S, Pagani E, Bonmassar E, et al: The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther. 2003, 304: 661-668. 10.1124/jpet.102.043950.CrossRef Pepponi R, Marra G, Fuggetta MP, Falcinelli S, Pagani E, Bonmassar E, et al: The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther. 2003, 304: 661-668. 10.1124/jpet.102.043950.CrossRef
19.
go back to reference Wright WE, Shay JW, Piatyszek MA: Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res. 1995, 23: 3794-3795. 10.1093/nar/23.18.3794.CrossRef Wright WE, Shay JW, Piatyszek MA: Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res. 1995, 23: 3794-3795. 10.1093/nar/23.18.3794.CrossRef
20.
go back to reference Wang Z, Kyo S, Maida Y, Takakura M, Tanaka M, Yatabe N, et al: Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene. 2002, 21: 3517-3524. 10.1038/sj.onc.1205463.CrossRef Wang Z, Kyo S, Maida Y, Takakura M, Tanaka M, Yatabe N, et al: Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene. 2002, 21: 3517-3524. 10.1038/sj.onc.1205463.CrossRef
21.
go back to reference Yagoa M, Ohkia R, Hatakeyamaa S, Fujitab T, Ishikawa F: Variant forms of upstream stimulatory factors (USFs) control the promoter activity of hTERT, the human gene encoding the catalytic subunit of telomerase. FEBS Lett. 2002, 520: 40-46. 10.1016/S0014-5793(02)02757-6.CrossRef Yagoa M, Ohkia R, Hatakeyamaa S, Fujitab T, Ishikawa F: Variant forms of upstream stimulatory factors (USFs) control the promoter activity of hTERT, the human gene encoding the catalytic subunit of telomerase. FEBS Lett. 2002, 520: 40-46. 10.1016/S0014-5793(02)02757-6.CrossRef
22.
go back to reference Andrews NC, Faller DV: A rapid micropreparation technique for extraction of DNA binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 1991, 19: 2499-10.1093/nar/19.9.2499.CrossRef Andrews NC, Faller DV: A rapid micropreparation technique for extraction of DNA binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 1991, 19: 2499-10.1093/nar/19.9.2499.CrossRef
23.
go back to reference Horikawa I, Barrett JC: Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis. 2003, 24: 1167-1176. 10.1093/carcin/bgg085.CrossRef Horikawa I, Barrett JC: Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis. 2003, 24: 1167-1176. 10.1093/carcin/bgg085.CrossRef
24.
go back to reference Hoos A, Hepp HH, Kaul S, Ahlert T, Bastert G, Wallwiener D: Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int J Cancer. 1998, 79: 8-12. 10.1002/(SICI)1097-0215(19980220)79:1<8::AID-IJC2>3.0.CO;2-5.CrossRef Hoos A, Hepp HH, Kaul S, Ahlert T, Bastert G, Wallwiener D: Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int J Cancer. 1998, 79: 8-12. 10.1002/(SICI)1097-0215(19980220)79:1<8::AID-IJC2>3.0.CO;2-5.CrossRef
25.
go back to reference Timeus F, Crescenzio N, Doria A, Foglia L, Pagliano S, Ricotti E, et al: In vitro anti-neuroblastoma activity of saquinavir and its association with imatinib. Oncol Rep. 2012, 27: 734-740. Timeus F, Crescenzio N, Doria A, Foglia L, Pagliano S, Ricotti E, et al: In vitro anti-neuroblastoma activity of saquinavir and its association with imatinib. Oncol Rep. 2012, 27: 734-740.
26.
go back to reference Piccinini M, Rinaldo MT, Anselmino A, Buccinnà B, Ramondetti C, Dematteis A, et al: The HIV protease inhibitors Nelfinavir and Saquinavir, but not a variety of HIV reverse transcriptase inhibitors, affect adversely human proteosome function. Antivir Ther. 2005, 10: 215-223. Piccinini M, Rinaldo MT, Anselmino A, Buccinnà B, Ramondetti C, Dematteis A, et al: The HIV protease inhibitors Nelfinavir and Saquinavir, but not a variety of HIV reverse transcriptase inhibitors, affect adversely human proteosome function. Antivir Ther. 2005, 10: 215-223.
27.
go back to reference Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ: HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res. 2005, 65: 8256-8265. 10.1158/0008-5472.CAN-05-1220.CrossRef Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ: HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res. 2005, 65: 8256-8265. 10.1158/0008-5472.CAN-05-1220.CrossRef
28.
go back to reference Furuya M, Tsuji N, Kobayashi D, Watanabe AN: Interaction between survivin and aurora-B kinase plays an important role in survivin-mediated up-regulation of human telomerase reverse transcriptase expression. Int J Oncol. 2009, 34: 1061-1068. Furuya M, Tsuji N, Kobayashi D, Watanabe AN: Interaction between survivin and aurora-B kinase plays an important role in survivin-mediated up-regulation of human telomerase reverse transcriptase expression. Int J Oncol. 2009, 34: 1061-1068.
29.
go back to reference Srirangam A, Milani M, Mitra R, Guo Z, Rodriguez M, Kathuria H, et al: The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. J Thorac Oncol. 2011, 6: 661-670. 10.1097/JTO.0b013e31820c9e3c.CrossRef Srirangam A, Milani M, Mitra R, Guo Z, Rodriguez M, Kathuria H, et al: The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. J Thorac Oncol. 2011, 6: 661-670. 10.1097/JTO.0b013e31820c9e3c.CrossRef
30.
go back to reference Gupta V, Samuleson CG, Su S, Chen TC: Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition. Neurosurg Focus. 2007, 23 (4): E9-10.3171/FOC-07/10/E9.CrossRef Gupta V, Samuleson CG, Su S, Chen TC: Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition. Neurosurg Focus. 2007, 23 (4): E9-10.3171/FOC-07/10/E9.CrossRef
31.
go back to reference Gregory MA, Hann SR: c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt’s lymphoma cells. Mol Cell Biol. 2000, 20: 2423-2435. 10.1128/MCB.20.7.2423-2435.2000.CrossRef Gregory MA, Hann SR: c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt’s lymphoma cells. Mol Cell Biol. 2000, 20: 2423-2435. 10.1128/MCB.20.7.2423-2435.2000.CrossRef
32.
go back to reference Henson SM, Macaulay R, Franzese O, Akbar AN: Reversal of functional defects in highly differentiated young and old CD8+ T cells by PDL blockade. Immunology. 2012, 135: 355-363. 10.1111/j.1365-2567.2011.03550.x.CrossRef Henson SM, Macaulay R, Franzese O, Akbar AN: Reversal of functional defects in highly differentiated young and old CD8+ T cells by PDL blockade. Immunology. 2012, 135: 355-363. 10.1111/j.1365-2567.2011.03550.x.CrossRef
33.
go back to reference Simsek BC, Pehlivan S, Karaoglu A: Human telomerase reverse transcriptase expression in colorectal tumors: correlations with immunohistochemical expression and clinicopathologic features. Ann Diagn Pathol. 2010, 14: 413-417. 10.1016/j.anndiagpath.2010.06.007.CrossRef Simsek BC, Pehlivan S, Karaoglu A: Human telomerase reverse transcriptase expression in colorectal tumors: correlations with immunohistochemical expression and clinicopathologic features. Ann Diagn Pathol. 2010, 14: 413-417. 10.1016/j.anndiagpath.2010.06.007.CrossRef
34.
go back to reference Prete SP, Aquino A, Masci G, Orlando L, Giuliani A, De Santis S, et al: Drug-induced changes of carcinoembryonic antigen expression in human cancer cells: effect of 5-fluorouracil. J Pharmacol Exp Ther. 1996, 279: 1574-1581. Prete SP, Aquino A, Masci G, Orlando L, Giuliani A, De Santis S, et al: Drug-induced changes of carcinoembryonic antigen expression in human cancer cells: effect of 5-fluorouracil. J Pharmacol Exp Ther. 1996, 279: 1574-1581.
35.
go back to reference Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG, et al: Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer. 2003, 104: 437-445. 10.1002/ijc.10969.CrossRef Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG, et al: Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer. 2003, 104: 437-445. 10.1002/ijc.10969.CrossRef
36.
go back to reference Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, et al: 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst. 2005, 97: 1437-1445. 10.1093/jnci/dji188.CrossRef Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, et al: 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst. 2005, 97: 1437-1445. 10.1093/jnci/dji188.CrossRef
37.
go back to reference Hoffman B, Liebermann DA: Apoptotic signaling by c-MYC. Oncogene. 2008, 27: 6462-6472. 10.1038/onc.2008.312.CrossRef Hoffman B, Liebermann DA: Apoptotic signaling by c-MYC. Oncogene. 2008, 27: 6462-6472. 10.1038/onc.2008.312.CrossRef
Metadata
Title
The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro
Authors
Riccardo Adamo
Alessandro Comandini
Angelo Aquino
Laura Bonmassar
Loredana Guglielmi
Enzo Bonmassar
Ornella Franzese
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2013
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-32-38

Other articles of this Issue 1/2013

Journal of Experimental & Clinical Cancer Research 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine